Analysed KURA ONCOLOGY INC (KURA:NASDAQ) News Sources
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
03-06-2026
yahoo.com
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions
06-06-2026
yahoo.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
11-06-2026
yahoo.com
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
30-06-2026
yahoo.com
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
07-07-2026
yahoo.com
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14-07-2026
yahoo.com
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
27-07-2026
yahoo.com
What is the current price of KURA ONCOLOGY INC (KURA:NASDAQ)?
The current price of KURA ONCOLOGY INC (KURA:NASDAQ) is $10.15.
KURA ONCOLOGY INC (KURA:NASDAQ) absolute price change since previous trading day?
The absolute price change of KURA ONCOLOGY INC (KURA:NASDAQ) since the previous trading day is $-0.24.
KURA ONCOLOGY INC (KURA:NASDAQ) percentage price change since previous trading day?
The percentage price change of KURA ONCOLOGY INC (KURA:NASDAQ) since the previous trading day is -2.3099%.
What is the most recent average sentiment score for KURA ONCOLOGY INC (KURA:NASDAQ)?
The most recent average sentiment score for KURA ONCOLOGY INC (KURA:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for KURA ONCOLOGY INC (KURA:NASDAQ)?
The most recent sentiment for KURA ONCOLOGY INC (KURA:NASDAQ) is .
SEC-8K** Filing Available For KURA ONCOLOGY INC (KURA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.